Financial Performance - The company's revenue for Q1 2023 was ¥157,152,422.97, representing a 30.02% increase compared to ¥120,869,514.08 in the same period last year[5] - Net profit attributable to shareholders reached ¥25,325,308.14, a significant increase of 159.52% from ¥9,758,558.93 year-on-year[5] - Basic earnings per share rose to ¥0.42, up 90.91% from ¥0.22 in the same period last year[5] - Total operating revenue for Q1 2023 was CNY 157,152,422.97, an increase of 30.0% compared to CNY 120,869,514.08 in Q1 2022[21] - Net profit for Q1 2023 reached CNY 25,325,308.14, representing a significant increase of 159.5% compared to CNY 9,758,558.93 in Q1 2022[22] - Earnings per share for Q1 2023 were CNY 0.42 (basic) and CNY 0.41 (diluted), compared to CNY 0.22 for both in Q1 2022[23] Cash Flow and Assets - The net cash flow from operating activities improved to ¥17,660,682.50, a turnaround from a negative cash flow of -¥22,515,151.37 in the previous year, marking a 178.44% increase[5] - Cash and cash equivalents at the end of the reporting period amounted to CNY 692.60 million, up from CNY 677.45 million at the beginning of the year[17] - The net cash flow from operating activities for the current period is CNY 17,660,682.50, compared to a loss of CNY 22,515,151.37 in the previous period, indicating a significant turnaround[26] - The ending balance of cash and cash equivalents was CNY 692,603,148.66, significantly higher than CNY 110,562,574.87 at the end of the previous period[26] Liabilities and Equity - Total assets at the end of the reporting period were ¥1,198,058,658.18, reflecting a 3.22% increase from ¥1,160,719,180.61 at the end of the previous year[5] - The company’s total liabilities decreased significantly, with accounts payable dropping by 85.70% to ¥1,393,710.82 from ¥9,747,127.73[10] - Total liabilities for Q1 2023 were CNY 217,053,366.30, slightly up from CNY 208,751,387.51 in the previous year[19] - The weighted average return on equity decreased to 2.62%, down from 4.17% in the previous year[5] Income and Investments - The company reported a significant increase in other income, totaling ¥7,504,421.66, which is a 356.94% rise compared to ¥1,642,329.68 in the previous year[10] - The company’s investment income surged to ¥865,047.41, a 300.13% increase from a loss of -¥432,245.20 in the same period last year[10] - The company reported a significant increase in investment income of CNY 865,047.41 compared to a loss of CNY 432,245.20 in Q1 2022[22] Operational Highlights - As of the end of the reporting period, the company had a total of 3,896 employees, with over 3,700 being professional staff[14] - The company has served nearly 800 clinical trial institutions, covering more than 1,300 institutions nationwide[14] - The company has undertaken over 2,500 international and domestic SMO projects, with 1,505 projects currently in execution[14] Research and Development - Research and development expenses for Q1 2023 were CNY 6,857,112.53, a slight increase from CNY 6,800,070.53 in the same period last year[22] Future Plans - The company plans to continue expanding its market presence and investing in new product development to sustain growth[20] Governance - The company successfully completed the election of its third board of directors and supervisory board on March 16, 2023[15] Audit Status - The company has not undergone an audit for the first quarter report[27]
普蕊斯(301257) - 2023 Q1 - 季度财报